Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 14/711,576, filed May 13, 2015. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,530,485 | Heteroaryl Substituted Pyrrolo[2,3-b]pyridines and Pyrrolo[2,3-b]pyrimidines as Janus Kinase Inhibitors In force · High confidence UsedRemaining | Incyte Holdings Corporation and Incyte Corporation | In force | High confidence | ||
| US 8,933,086 | Heteroaryl Substituted Pyrrolo[2,3-b]pyridines And Pyrrolo[2,3-b]pyrimidines As Janus Kinase Inhibitors In force · High confidence | Incyte Holdings Corporation and Incyte Corporation | In force | High confidence | ||
| US 8,946,245 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS In force · High confidence | Incyte Holdings Corporation and Incyte Corporation | In force | High confidence | ||
| US 9,079,912 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | Incyte Holdings Corporation and Incyte Corporation | In force | High confidence | ||
| US 9,206,187 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | Incyte Holdings Corporation and Incyte Corporation | In force | High confidence | ||
| US 9,662,335 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | Incyte Holdings Corporation | In force | High confidence | ||
| US 9,814,722 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | Incyte Holdings Corporation | In force | High confidence | ||
| US 9,974,790 | Heteroaryl Substituted Pyrrolo[2,3-b] Pyridines And Pyrrolo[2,3-b] Pyrimidines As Janus Kinase Inhibitors In force · High confidence | Incyte Holdings Corporation | In force | High confidence | ||
| US 10,398,699 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS In force · High confidence | Incyte Holdings Corporation | In force | High confidence | ||
| US 10,639,310 | Heteroaryl Substituted Pyrrolo[2,3-b]pyridines and Pyrrolo[2,3-b]pyrimidines as Janus Kinase Inhibitors In force · High confidence | Incyte Holdings Corporation | In force | High confidence | ||
| 7 more records in this group · Pro | ||||||
10 of 17 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 17, including 15 expiring within the 18 months from Nov 21, 2026.
7 of these are in force and held by Incyte Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.